Cantor Fitzgerald Weighs in on ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology company will earn ($0.54) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.81) per share.

Other analysts have also recently issued reports about the stock. HC Wainwright upgraded Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Monday, December 23rd. BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Tuesday, November 19th. Piper Sandler raised Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $3.00 to $13.00 in a research report on Monday, November 18th. Leerink Partners upgraded Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $2.00 to $7.00 in a research note on Tuesday, November 19th. Finally, Leerink Partnrs raised shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Aclaris Therapeutics presently has a consensus rating of “Buy” and an average target price of $11.00.

Aclaris Therapeutics Price Performance

ACRS opened at $2.60 on Wednesday. The stock has a market capitalization of $185.72 million, a price-to-earnings ratio of -5.00 and a beta of 0.54. Aclaris Therapeutics has a 12 month low of $0.95 and a 12 month high of $5.17. The business has a 50-day moving average of $3.09 and a two-hundred day moving average of $1.95.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Trium Capital LLP grew its holdings in shares of Aclaris Therapeutics by 1.1% in the 3rd quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company’s stock worth $2,200,000 after acquiring an additional 20,940 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Aclaris Therapeutics by 1.9% in the second quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock worth $3,671,000 after buying an additional 63,358 shares during the period. Geode Capital Management LLC increased its position in shares of Aclaris Therapeutics by 9.3% in the third quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock worth $974,000 after acquiring an additional 72,309 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Aclaris Therapeutics during the second quarter valued at approximately $119,000. Finally, Assenagon Asset Management S.A. acquired a new position in Aclaris Therapeutics in the 3rd quarter worth approximately $214,000. Institutional investors own 98.34% of the company’s stock.

Insider Activity at Aclaris Therapeutics

In other Aclaris Therapeutics news, Director Anand Mehra purchased 666,666 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was bought at an average cost of $2.25 per share, with a total value of $1,499,998.50. Following the acquisition, the director now owns 710,030 shares of the company’s stock, valued at $1,597,567.50. The trade was a 1,537.37 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.40% of the stock is currently owned by insiders.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.